drugset
drugset / Trial / NCT01579526

A Single Dose Study to Determine the Safety and Pharmacokinetics of FP01 Lozenges in Healthy Volunteers

NCT01579526 ↗

Phase 1 Completed 40 enrolled Avalo Therapeutics, Inc.
RandomizedParallel-groupOpen-labelBasic science

Summary

The purpose of this study is to determine the safety and pharmacokinetics of FP01 in healthy volunteers.

Timeline

Start
2012-04
Primary completion
2012-04
Completion
2012-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Memantine Unknown — —

Indications

No indication recorded.